WW (tryptophan)-activated extracellular vesicle vaccine platform

Overview

The WAEV — WW (tryptophan)-activated Extracellular Vesicle Vaccine Platform by Vesimmune represents an innovative approach to vaccine delivery. This platform leverages the unique ability to efficiently bud vesicles from producer cells by fusing a transmembrane protein target to WW domains. This process ensures that the vesicles are loaded with the target protein during production, avoiding costly post-loading processes, while maintaining the protein's natural conformation. These vesicles are also multivalent, presenting multiple antigens, and are stable for extended periods at room temperature, making them highly effective for vaccine applications.

Technical specifications

Key features:

• Efficient Vesicle Budding: Utilizes WW domains to drive robust vesicle budding from cell membranes.
• Biological Loading: Simultaneous loading of the transmembrane protein during vesicle production.
• Natural Conformation: Maintains the protein's natural epitope structure by associating it with the lipid bilayer.
• Stability: Multivalent vesicles stable for at least 45 days at room temperature.
• Scalability: Easily scalable platform with low production costs.
• Effectiveness: Proven in universal flu applications with higher antibody titers and durable responses.

Technology readiness level

The WAEV platform is currently at Technology Readiness Level 4, having been validated in universal flu applications. Vesimmune is seeking opportunities for further development through sponsored research and co-development partnerships, aiming to expand this platform to new indications.